MicroVention, Inc., d/b/a Terumo Neuro appears in FDA records as the applicant for the Mayumi™ Thrombectomy System, cleared as substantially equivalent on September 3, 2026. The same organization publishes under the Terumo Neuro name, which it adopted after its 2006 acquisition by Terumo Corporation. Its stated focus is neuroendovascular devices, including catheters and guidewires for accessing and treating neurovascular lesions. [1][2][4][5]
The Mayumi™ Thrombectomy System filing
K254035 lists MicroVention, Inc., d/b/a Terumo Neuro as applicant for the Mayumi™ Thrombectomy System, an aspiration thrombectomy catheter under 21 CFR 870.5150, product code QEZ, Class II. FDA recorded the submission as received December 16, 2025, with a decision date of September 3, 2026 and decision code SESE, substantially equivalent. The clearance letter carries a July 31, 2026 dating and an August 3, 2026 receipt date, and names product codes QEZ and KRA. [1][2]
The filing describes a system configuration of an aspiration catheter in 20 Fr or 24 Fr, a 60 cc locking syringe, a dilator and a Y-connector. The syringe is described as creating a vacuum for clot removal, and the Y-connector attaches to the proximal Luer connector on the dilator for flushing. [2]
Company identity and brand lineage
Terumo Neuro states that MicroVention was founded in Southern California in 1997, was acquired by Terumo Corporation in 2006, and by 2024 had transitioned into Terumo Neuro. A company press release announces the rebrand from MicroVention to Terumo Neuro and describes the change as reflecting an expanded focus and strategic growth. Terumo Corporation is identified as a parent in that release and in Terumo Neuro's own description of itself as a wholly owned subsidiary. [4][6][8]
The FDA applicant name and the commercial brand are therefore distinct labels for the same organization: the regulatory filings use the MicroVention legal name with the Terumo Neuro trade designation, while company-published material uses Terumo Neuro. The Aliso Viejo, California address in the FDA correspondence is a filing address and is not presented here as a headquarters. [1][2][4]
Documented product scope
Terumo Neuro's own pages describe catheter-based, minimally invasive neuroendovascular technologies for neurovascular disorders, naming ischemic stroke and brain aneurysms as target conditions. The company lists access devices, including micro catheters and guidewires, as products that allow physicians to reach treatment areas in the brain. [5][6]
Featured products on the company site include FRED™ X, described as flow diversion technology, the WEB™ Embolization System, described as intrasaccular devices, BOBBY™ balloon guide catheters and the SOFIA™ Plus distal access catheter. Terumo notes that regulatory approval status and availability of these products differ by country or region. [5][6]
What the supplied filings establish
The supplied collection contains one linked 510(k) record, K254035, with a single SESE decision; the record sample contains the same one entry, so the sample and collection are equal in size. This count is an as-of snapshot of the supplied filings and does not represent total company sales, total portfolio or safety performance. [1]
Beyond K254035, the public documents do not document additional clearances, recalls or post-market results for this applicant. A company news item references publication of RESTORE registry results in the Journal of NeuroInterventional Surgery, but the public information does not include the registry data itself. [1][6]
